Speech, Linguistic and Acoustic Markers in Parkinson's Disease
NCT ID: NCT04273672
Last Updated: 2025-06-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
58 participants
OBSERVATIONAL
2020-01-13
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Voice Treatment for Parkinson's Disease
NCT00123084
Spoken Discourse Biomarker of PD Cognitive Impairment
NCT05909163
Intelligibility Assessment for Parkinson's Disease
NCT04829006
Neuroplasticity in Parkinson's Disease
NCT05286736
Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease
NCT06540989
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parkinson's Disease
Subjects with Parkinson's Disease
Cognitive Battery
Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
Voice, Speech and Language Analysis
Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
Questionnaires and Clinical Assessments
Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
DNA Analysis
Participants will have their blood drawn for DNA analysis.
Control
Subjects without Parkinson's Disease
Cognitive Battery
Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
Voice, Speech and Language Analysis
Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
Questionnaires and Clinical Assessments
Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cognitive Battery
Participants will be asked to complete a series of cognitive testing (testing of concentration, memory, and other thinking abilities).
Voice, Speech and Language Analysis
Participants will be asked to perform speaking and reading tasks, which will be recorded. Participants will be asked to complete a laptop-based test of language comprehension.
Questionnaires and Clinical Assessments
Participants with Parkinson's disease will complete an examination of their symptoms and questionnaires assessing disease symptoms, mood and activities of daily living. Healthy controls participants will be asked to complete questionnaires on mood.
DNA Analysis
Participants will have their blood drawn for DNA analysis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Disease duration ≥ 2 years
* Mild cognitive impairment or normal cognition
Exclusion Criteria
* Adults unable to consent
* Age \< 18
* Pregnant women
* Prisoners
* Non-English speakers
* Any neurological disorder other than PD
* Deep brain stimulator placement
* Severe, unstable psychiatric disorder
* Unintelligible speech due to effects of PD
* Visual acuity or color vision impairment that would interfere with cognitive testing
* Other voice, speech or swallowing disorders or history of surgery involving palate/nasopharynx/larynx/vocal cords
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boston University
OTHER
VA Puget Sound Health Care System
FED
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Massachusetts Institute of Technology/Lincoln Labs
UNKNOWN
University of Massachusetts, Worcester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kara Smith
Assistant Professor of Neurology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kara Smith, MD
Role: PRINCIPAL_INVESTIGATOR
UMass Medical School
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UMass Medical School/UMass Memorial Medical Center
Worcester, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H00011523
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.